Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$2.19B |
| 2 |
GE Vernova
GEV
|
+$1.16B |
| 3 |
Meta Platforms (Facebook)
META
|
+$501M |
| 4 |
Palantir
PLTR
|
+$451M |
| 5 |
DoorDash
DASH
|
+$411M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.22B |
| 2 |
Ascendis Pharma A/S
ASND
|
+$866M |
| 3 |
Applovin
APP
|
+$690M |
| 4 |
DAY
Dayforce
DAY
|
+$576M |
| 5 |
Workday
WDAY
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.5% |
| 2 | Healthcare | 20.49% |
| 3 | Industrials | 11.17% |
| 4 | Consumer Discretionary | 9.27% |
| 5 | Communication Services | 8.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Liberty Media Series A
FWONA
$22.3B
| $78.6M | 0.04% |
1,006,144
+10,603
| +1% | +$848K |
|
327
Wabtec
WAB
$51.1B
| $78.3M | 0.04% |
313,398
+1,025
| +0.3% | +$248K |
|
328
Colliers International
CIGI
$4.98B
| $78.1M | 0.04% |
725,961
+76,588
| +12% | +$9.55M |
|
|
TERN
329
DELISTED
Terns Pharmaceuticals
TERN
| $77.5M | 0.04% |
1,470,057
-1,909,512
| -57% | -$78.4M |
|
330
Stantec
STN
$7.69B
| $77.3M | 0.04% |
903,925
-2,547
| -0.3% | -$240K |
|
331
Relmada Therapeutics
RLMD
$544M
| $76.9M | 0.04% |
11,063,862
+3,793,862
| +52% | +$17.9M |
|
332
Zscaler
ZS
$23B
| $76M | 0.04% |
541,671
+173,268
| +47% | +$30.7M |
|
333
Mirion Technologies
MIR
$4.05B
| $75.2M | 0.04% |
4,043,089
-553,860
| -12% | -$12.5M |
|
334
Mueller Industries
MLI
$14.1B
| $74.9M | 0.04% |
1,352,104
+140,866
| +12% | +$8.45M |
|
335
Littelfuse
LFUS
$10.2B
| $74.2M | 0.04% |
218,571
-468
| -0.2% | -$152K |
|
336
Becton Dickinson
BDX
$43.1B
| $73.5M | 0.04% |
467,396
+46,157
| +11% | +$8.47M |
|
337
IBM
IBM
$202B
| $73.4M | 0.04% |
302,610
-9,634
| -3% | -$2.61M |
|
338
Global E Online
GLBE
$6.08B
| $72.8M | 0.03% |
2,360,866
+91,384
| +4% | +$3.21M |
|
339
Jacobs Solutions
J
$15.9B
| $72.5M | 0.03% |
569,689
+101,137
| +22% | +$13.7M |
|
340
NewAmsterdam Pharma
NAMS
$3.47B
| $72.3M | 0.03% |
2,258,984
-82,739
| -4% | -$2.7M |
|
341
Toll Brothers
TOL
$14B
| $72.2M | 0.03% |
528,903
+62,168
| +13% | +$9.13M |
|
342
Monopar Therapeutics
MNPR
$736M
| $72.1M | 0.03% |
1,317,410
| – | – |
|
343
HealthEquity
HQY
$7.91B
| $71.1M | 0.03% |
850,411
+30,178
| +4% | +$2.48M |
|
344
Sportradar
SRAD
$4.23B
| $69.6M | 0.03% |
4,157,470
+1,306
| +0% | +$24.3K |
|
345
Amylyx Pharmaceuticals
AMLX
$2.05B
| $69.3M | 0.03% |
4,986,073
+520,201
| +12% | +$7.32M |
|
346
Entergy
ETR
$54.1B
| $69.1M | 0.03% |
614,906
+87,561
| +17% | +$8.81M |
|
347
Krystal Biotech
KRYS
$9.88B
| $68.9M | 0.03% |
266,659
+47,219
| +22% | +$12.6M |
|
348
Ametek
AME
$55.5B
| $68.8M | 0.03% |
321,113
-78,040
| -20% | -$17.3M |
|
349
Insmed
INSM
$23.2B
| $68.6M | 0.03% |
419,304
-381,251
| -48% | -$58.6M |
|
350
L3Harris
LHX
$55.9B
| $68.5M | 0.03% |
198,606
-31,565
| -14% | -$11M |
|
Similar funds
Janus Henderson Group's Q1 2026 Portfolio in Review
As of Q1 2026, Janus Henderson Group held 2,488 positions worth $209B, down 6.2% from $223B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Janus Henderson Group's Q1 2026 filing shows 82 new, 739 increased, 627 reduced and 81 closed positions. Its largest new stake was Forgent Power Solutions: 7,769,612 shares worth $227M. The largest sale was Microsoft, an estimated $1.22B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 35% a quarter earlier, followed by Healthcare and Industrials.
- Janus Henderson Group's largest Q1 2026 buy was Forgent Power Solutions: 7,769,612 shares worth $227M.
- Janus Henderson Group added most to AstraZeneca in Q1 2026, an estimated $2.19B increase.
- Janus Henderson Group's biggest Q1 2026 reduction was Microsoft, cutting an estimated $1.22B.
- Janus Henderson Group fully exited Ascendis Pharma A/S in Q1 2026, selling an estimated $866M.
- Janus Henderson Group's ten largest holdings make up 30% of its $209B portfolio in Q1 2026.
- Janus Henderson Group opened 82 new positions and closed 81 in Q1 2026.
- Janus Henderson Group's portfolio value fell 6.2% quarter-over-quarter to $209B.
Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.